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It is generally accepted that the immune system plays an important role in controlling tumour development. However, the interplay
between tumour and immune system is complex, as demonstrated by the fact that tumours can successfully establish and develop
despite the presence of T cells in tumour. An improved understanding of how tumours evade T-cell surveillance, coupled with
technical developments allowing the culture and manipulation of T cells, has driven the exploration of therapeutic strategies based on
the adoptive transfer of tumour-specific T cells. The isolation, expansion and re-infusion of large numbers of tumour-specific T cells
generated from tumour biopsies has been shown to be feasible. Indeed, impressive clinical responses have been documented in
melanoma patients treated with these T cells. These studies and others demonstrate the potential of T cells for the adoptive therapy
of cancer. However, the significant technical issues relating to the production of natural tumour-specific T cells suggest that the
application of this approach is likely to be limited at the moment. With the advent of retroviral gene transfer technology, it has
become possible to efficiently endow T cells with antigen-specific receptors. Using this strategy, it is potentially possible to generate
large numbers of tumour reactive T cells rapidly. This review summarises the current gene therapy approaches in relation to the
development of adoptive T-cell-based cancer treatments, as these methods now head towards testing in the clinical trial setting.
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The immune system has developed in order to protect against
infection by pathogens and thereby prevent disease. With a greater
understanding of immune cell function, there is now an increased
awareness that the immune system actually plays a critical role in
cancer prevention (Zou, 2005). Delineating this role of the immune
system remains a key goal of basic research; however, the
implication of these observations is that manipulating and
boosting the power of the immune system may prove to be a
potent cancer therapy (Murphy et al, 2005).
To this end, immune cells themselves are being increasingly
investigated for potential cancer therapies, with a great deal of
interest now focused on T cells in particular (Rosenberg et al,
2004). T cells are key effector cells of the adaptive immune system
that perform critical activities, which includes target cell lyses,
while working in conjunction with other immune cells to
orchestrate the immune response through the timed production
of cytokines (Shankaran et al, 2001). T cells respond to antigen as a
result of the precise interaction of the T-cell receptor (TCR) with
antigens presented on target cells. The antigen consists of peptides
of varying lengths presented in the binding groove of molecules
called the major histocompatibility complex (MHC). Critically, the
type of T cell activated is dependent on the MHC presenting the
peptide antigen. All nucleated cells express MHC class I proteins
that can present antigens to CD8
þ expressing T cells, while a more
restricted sub-set of cells (generally called antigen-presenting cells
(APCs)) express MHC class II, which specifically activate CD4
þ T
cells. The general defining features of these two sub-sets of T cells
are that CD8
þ T cells are considered to be the predominant
cytotoxic cells (Tc) while CD4
þ T cells are thought to play a
critical role in refining and optimising T cell and other immune
cell responses and so are commonly referred to as helper T cells
(Th). It is clear that these separations are simplistic and may not
entirely reflect the in vivo functions of the T-cell lineages; however,
these distinctions are relevant for a consideration of how T cells
can be used for cancer therapy (Figure 1).
ADOPTIVE T-CELL THERAPY: ALLOGENEIC T CELLS
FOR HAEMOPOIETIC MALIGNANCIES
The power of adoptive T-cell therapy has been clearly demon-
strated using donor lymphocyte infusions (DLI) for the treatment
of a number of haematological malignancies (Kolb et al,
1995). Lymphocytes isolated from an allogeneic donor and
given to a patient are thought to respond to tumour through
MHC mismatches (either major or minor MHC mismatches)
and subsequently eliminate tumour (the graft-vs-tumour effect).
However, by the same process, they are also destructive
to healthy host tissue. This unwanted side effect, graft-vs-host
disease (GvHD), is associated with high rates of morbidity and
mortality. This has limited the use of such therapy to a
few specialist hospitals, where many strategies have been employed
to control such toxicity (Goker et al, 2001). However, T cells are
the critical component since their depletion from the DLI
abrogates both graft-vs-leukaemia and GvHD effects (Maraninchi
et al, 1987).
Received 20 April 2005; revised 1 September 2005; accepted 7
September 2005; published online 25 October 2005
*Correspondence: Professor RE Hawkins;
E-mail: robert.e.hawkins@manchester.ac.uk
British Journal of Cancer (2005) 93, 1085–1091
& 2005 Cancer Research UK All rights reserved 0007– 0920/05 $30.00
www.bjcancer.comIn order to control GvHD, a novel method is being explored
whereby the donor lymphocytes are gene modified to express a
suicide gene. The general approach involves the ex vivo transduc-
tion of lymphocytes present within the DLI with a retrovirus
encoding the suicide gene (e.g. herpes simplex virus thymidine
kinase) (Bonini et al, 1997). The DLI is then infused into the
patient and, should GvHD develop, the prodrug metabolised by the
suicide gene (gancyclovir) is administered to the patient, with the
result that the donor T cells are specifically killed thereby
controlling toxicity and GvHD (Bonini et al, 1997). Unfortunately,
the antitumour response is also diminished as a result of the
suicide gene system.
ADOPTIVE T-CELL THERAPY – ‘NATURAL’ T CELLS
Studies focusing on the use of nonspecific modulators of immune
activity such as IL-2 have demonstrated that creditable clinical
responses can be achieved in certain tumour types, including
melanoma and renal cell cancer (Fyfe et al, 1995; Atkins et al,
1999). These studies have encouraged the development of targeted
therapies and, specifically, the clinical testing of antigen-specific T
cells for the treatment of melanoma. Antigen-specific T cells
isolated directly from tumour biopsies (tumour infiltrating
lymphocytes (TILs)) are identified by observing their functional
response against melanoma antigens and then subsequently
expanded ex vivo by IL-2-driven expansion regimes (Dudley
et al, 2002a). While these results have been extensively reviewed
(Rosenberg and Dudley, 2004), it is important to consider the
salient points of these studies as a platform to consider gene-
modified T cells for future clinical studies. A key observation made
from these studies showed that both CD4
þ and CD8
þ T cells are
required in order to generate an effective response in vivo (Dudley
et al, 2001, 2002b). Furthermore, modulation or elimination of the
patient’s immune system prior to re-infusion of the expanded T
cells was advantageous. A nonmyeloablative preconditioning
chemotherapy using cyclophosphamide and fludarabine effectively
removed all leukocytes from the patient. The tumour-specific T
cells were then re-infused and supported with high-dose IL-2
infusions (Dudley et al, 2002b). Interestingly, clinical responses
correlated with T-cell persistence in vivo, suggesting that survival
of the T cells was critical to a successful outcome (Meidenbauer
et al, 2003). It is not clear whether the beneficial effect of
preconditioning was a result of ‘free-space’ created for engraftment
through the removal of competing leukocytes or whether the
preconditioning had removed important regulatory influences,
such as regulatory T cells, thereby allowing the infused T cells to
function in a more-friendly immune responsive environment.
These studies clearly demonstrated the in vivo effectiveness of
antigen-specific T cells and also illustrate that manipulating the
environment into which the T cells were being re-infused was also
critical. However, it is also clear that generating antigen-specific T
cells is highly demanding and requires specialised technical
expertise, facilities and equipment. This is due to the fact that
antigen-specific T cells represent a very small fraction of the total
T-cell population. Subsequently, isolating this small number of
cells and expanding them to clinically relevant numbers is an issue
of significant proportions. Furthermore, many tumour types do
not have a significant TIL population or the tumours themselves
are not amenable to surgical removal and/or dissection in order to
isolate TILs. Consequently, to date, attempts to use TIL therapy
have been effectively restricted to trials in renal cell carcinoma and
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Figure 1 Generation of tumour antigen-specific T cells. Different strategies have been employed to endow T cells with the specificity and power to
specifically kill tumour. Large numbers of host T cells can be modified to become tumour reactive by transducing them to express. (A) Chimeric immune
receptors or (B) tumour-specific T-cell receptors using retroviral technology. (C) Tumour reactive T cells are identified and grown out of a population of
tumour infiltrating lymphocytes. These cells are then expanded for use.
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approaches have been explored in order to facilitate the generation
of antigen-specific T cells from peripheral blood.
T CELLS ENGINEERED TO EXPRESS RECOMBINANT
TCR GENES
T cells recognise MHC-peptide conjugates on target cells through
the paired a and b chains of the TCR. This pairing confers the
antigen specificity of the T cell. One gene therapy approach has
involved the molecular cloning of the TCR genes known to be
specific for an antigen of choice. These chains are then introduced
into T cells usually by means of a retroviral vector. Consequently,
expression of the cloned TCRa and TCRb genes endows the
transduced T cell with a functional specificity determined by the
pairing of these new genes. In this manner, large numbers of
antigen-specific T cells can be generated in a short time period as
compared to the longer term culture issues concerning the large-
scale expansion of ‘natural T cells’.
There are a number of practical and theoretical issues that are
currently being addressed by workers in the field, and recent
reviews have provided an in-depth discussion of this specific area
(Schumacher, 2002; Willemsen et al, 2003; Stauss et al, 2004). With
relevance to this review, there are three principal issues concerning
TCR-based gene therapy, which are of broad relevance to
oncologists: isolation and expression of the TCR genes, safety
and clinical application.
Isolation and expression of suitable TCRa and TCRb
chains
The general methodology involves the isolation of T cells
that functionally respond to the target antigen from which
the TCR chains are cloned using polymerase chain reaction
(PCR)-based methods. The resultant DNA products are sequenced
to confirm identity and then placed into retroviral vectors
suitable for expression in T cells (Clay et al, 1999). T-cell receptor
chains to date have been generated against known antigens
with the principal targeted disease being melanoma due to the
fact that MHC restricted antigens are numerous and well
defined (Rivoltini et al, 2002). Aside from melanoma, there
is an increasing diversity of targets being exploited for TCR
therapy including MDM-2, a potential target in a wide
range of malignancies (Stanislawski et al, 2001) and WT-1
targeting in leukaemia (Xue et al, 2004). However, the
rate-limiting step is the identification and isolation of the
critical responding T cell to serve as a source to generate
the TCR genes with (generally speaking) a great deal of effort
generally required to generate antigen-specific T cells. Develop-
ment of methodologies that will permit the rapid isolation of TCR
genes remains a critical area of development, especially when
considering that, for widespread use, TCR genes for each HLA type
will be required in order to treat every cancer patient (Murphy
et al, 2005).
In order to generate a functional T-cell response, both TCRa and
TCRb genes need to be efficiently introduced into the T cell and
expressed to levels that will permit sufficient paired complexes to
be present on the surface of the transduced T cell. Retroviral gene
transfer technologies have been the method of choice since these
vectors can efficiently transduce primary T cells (Movassagh et al,
2000). Importantly, current retroviral vectors based on the murine
leukaemia virus family require the target cell to be undergoing
rapid cell cycling to permit efficient transduction (Miller et al,
1990). With respect to T cells, cell cycling is stimulated by the
activation of T cells using strong mitogenic stimuli (with lectins or
antibodies), and this may have a profound effect on the subsequent
functionality of the transduced T-cell populations. Other vector
systems are being investigated (Chinnasamy et al, 2000; Jensen
et al, 2000); however, these murine retroviral vectors possess a
clinical pedigree (Bonini et al, 2003) and so remain the principal
choice for TCR-based approaches. Expression of multiple TCR
genes has been achieved through a number of methods, including
transduction with multiple retroviruses encoding single genes
(Schaft et al, 2003) or single vectors employing internal ribosome
entry sites for multiple gene expression (Morgan et al, 2003),
although further improvements in vector design are required in
order to ensure the high-level expression of multiple genes in
retroviral vectors.
Critically, primary human T cells transduced with retroviral
vectors encoding TCRs functionally respond against tumour cells
expressing the target antigen. These responses include cytokine
release, proliferation and cytotoxicity (Gao et al, 2003; Morgan
et al, 2003; Schaft et al, 2003), indicating that the overall strategy is
highly effective in directing the functional activities of T cells.
However, the majority of TCRs cloned to date are MHC class I
specific and, consequently, direct the functional activity of CD8
þ
T cells. Encouragingly, these MHC class I restricted TCR genes also
appear to function in CD4
þ T cells (Morris et al, 2005), suggesting
that a polyclonal T-cell response consisting of both CD4 and CD8 T
cells is feasible using a single TCR pairing.
Safety
Tumorigenesis as a result of retroviral insertional mutagenesis
has been documented in the case of engineered stem cell therapy
for X-linked SCID (Hacein-Bey-Abina et al, 2003). However,
at present, there are no examples of clinical manifestation of
insertional mutagenesis associated with genetic modification of
differentiated T cells (Bonini et al, 2003), suggesting that the
same safety issues which are evident in stem cell therapy
approaches are a less significant issue in differentiated
T-cell therapy (Stauss et al, 2004). However, a specific concern
with TCR-based therapy is the fact that the new TCR genes could
pair with endogenous TCR genes, with the possible result that T
cells with a new and autoimmune specificity could be generated.
The probability of this occurring is unknown and the potential
danger has to be carefully assessed and balanced against the
potential benefit of treating patients with advanced disease.
However, more recent studies have focused up engineering the
antigen-specific TCRs in order to prevent pairing with endogenous
TCR genes (Willemsen et al, 2000).
Clinical application
An important final issue concerning the use of TCR therapy is the
fact that dealing with specific TCRs will mean restricting the target
patient group to those expressing the correct MHC haplotype,
while the reliance upon tumour expression of MHC is central to
the therapy. The majority of ongoing studies have focused upon
targeting more common MHC haplotypes, however, for wide-
spread application numerous TCR combinations for specific target
antigens will have to be developed and validated.
A further complicating factor is that these gene-modified T cells
are dependent on the antigen presentation machinery of the
tumour. Critically, MHC downregulation is a commonly observed
feature of tumours (Garrido et al, 1997). In the absence of a
suitable MHC-peptide target on the surface of the tumour, T cells
expressing tumour-specific TCR genes would be unlikely to
respond against the target. Modulation of MHC expression on
tumours is possible; however, in the light of these observations,
targeting of T cells to recognise intact cell surface protein antigens
using antibody-based technologies, thereby avoiding tumour
antigen presentation mechanisms, has been the focus of an
increasing number of research groups.
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The basis of this field resides in studies performed in the late
1980s, when it was demonstrated that a receptor consisting of a
fusion of an antibody domain with the TCRb chain could direct T-
cell hybridomas to respond against the protein antigen targeted by
the antibody. This showed that T cells could respond to antigen
independent of TCR–MHC interaction (Gross et al, 1989). Given
that tumours can frequently lose antigen expression through
factors such as the downregulation of MHC expression (Garrido
et al, 1997), this makes antibody targeted T cells highly attractive.
The subsequent 15 years have seen the rapid development of
chimeric immune receptor (CIR) technology through to current
testing in ongoing phase I clinical trials. Various recent publica-
tions have extensively reviewed this area (Hombach et al, 2002;
Thistlethwaite et al, 2005). The aim here is to provide an overview
of the current state of antibody targeted T-cell research and to
discuss some key scientific areas that are likely to affect upon the
immediate translation of this therapy into clinical practice.
T cells using CIRs to target cellular antigens depend on the
introduction of a gene encoding the receptor into the T cell. The
essential components of a CIR are an antigen targeting domain
fused to an intracellular signalling domain anchored to the surface
of the T cell by a transmembrane domain (Figure 2). The antigen
binding domain most commonly involves a single chain antibody
fragment (scFv) consisting of the antigen recognition components
of a monoclonal antibody (Gross et al, 1989; Hawkins et al, 1998),
although other protein domains have been successfully used
(Mitsuyasu et al, 2000). The scFv maintains the specificity of the
original antibody, but carries the advantage of small size suitable
for expression as part of a CIR. The predominant requisite for the
targeted tumour antigen is cell surface expression. Aside from this,
the diversity of antigens targeted to date is extensive with the
majority of cancer types represented (Table 1).
The signalling domains used have focused on the key signalling
molecules CD3z and the g chain from FceRI. A wide number of
laboratories have confirmed that CIRs expressed in primary T cells
elicit functional responses when cultured with cells expressing the
target protein antigen or even purified proteins immobilised on a
surface (e.g. on a culture plate) (Haynes et al, 2001). These
functional responses (including cytotoxicity and cytokine produc-
tion) are those thought to be important for antitumour activity. A
more recent development has involved the engineering of CIRs to
incorporate multiple signalling domains. The first receptor of this
type involved a fusion of the CD28 receptor with the CD3z moiety
(Finney et al, 1998). For full activation of the T cell, multiple
signals are required. The TCR/CD3z complex generates the
antigen-specific response of the T cell (namely cytotoxicity and
cytokine production). However, in the absence of associated
stimuli (so-called costimulatory signals), the T-cell falters during
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Figure 2 The chimeric immune receptor. (A) The T-cell receptor composed of the a and b chains transmits its signal through the CD3 molecule (g, e, d
and z moieties) following interaction with MHC/epitope complex. This differs from the chimeric immune receptor (B) which is composed of an extracellular
single chain antibody recognition domain connected to signalling moiety shown in this example as either the CD3 z molecule (C) or as a fusion receptor
using the CD28 molecule proximal to the z moiety. Activation of the chimeric immune receptor can be initiated in the presence of tumour antigen in an
MHC independent manner.
Table 1 Viral/tumour associated antigens targeted by chimeric immune
receptor T cells
Targeted antigen Target cells Reference
CD20 B cell lymphoma Jensen et al (2003)
CD30 Hodgkin’s lymphoma Hombach et al (2001)
CEA Gastrointestinal tumours Gilham et al (2002)
ErbB-2 Breast, ovarian carcinoma Altenschmidt et al (1997)
G250 Renal cell carcinoma Weijtens et al (2000)
Gp120 HIV Walker et al (2000)
MAGE-EA1 Melanoma Willemsen et al (2000)
NCAM Neuroblastoma Gilham et al (2002)
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Karjalainen, 1995). Costimulatory signals generated through
receptors such as CD28 reinforce the TCR/CD3z signal through
further cytokine release (including IL-2) and the upregulation of
key antiapoptotic gene expression (Krause et al, 1998). Fusion
CIRs encoding both CD28 and CD3z signalling domains
(Figure 2C) would be predicted to function more optimally than
a CD3z-only receptor since activatory and costimulatory signals
would be generated from the same receptor. Indeed, this appears
to be the case, with a growing number of reports confirming that T
cells expressing CD28-z fusion CIRs when stimulated express IL-2
and appear to demonstrate improved antitumour activity in vitro
and in vivo (Eshhar et al, 2001; Haynes et al, 2002; Maher et al,
2002). Driven by the relative success of the CD28-based receptors,
other known T-cell costimulatory receptors are being tested as
CIRs, with the majority appearing to bring significant improve-
ments to the CD3z receptor (Finney et al, 2004; Imai et al, 2004).
Once again, there are certain key issues concerning antibody
targeted T cells that are likely to be of primary interest to
oncologists. These include antigen selection/selection of targeting
moiety, safety and clinical application.
Antigen selection/selection of targeting moiety
The key attractive feature of this approach is the generic nature of
the targeting construct. Since the target is typically a cell surface
expressed tumour associated antigen (TAA), the scFv (or other
moiety) is not restricted by HLA expression and, subsequently, a
single receptor is broadly applicable to all cancer patients as long
as the target antigen is expressed on the tumour. Furthermore,
with the development of powerful scFv selection technologies (e.g.
phage display (Winter et al, 1994)), scFv can, at least in theory, be
rapidly generated against any protein antigen. However, the
selection of the target antigen is of critical importance since the
expression of the target antigen on normal tissues could result in
toxicity (discussed below).
Safety
The issues of retroviral insertional mutagenesis apply to antibody
targeted T cells as for TCR gene therapy as discussed previously.
However, clinical trials are ongoing, where plasmid-mediated gene
transfer has been used to avoid some of the issues with retroviral
gene transfer. However, this approach is still likely to suffer from
the same potential problems of insertional mutagenesis due to
integration of the construct into the genome of the T cell.
The issue of target antigen selection is of major importance. The
majority of TAAs are antigens, which are overexpressed on
tumours. However, expression of these antigens is not restricted to
tumour with antigens typically expressed on normal tissues. For
example, carcino-embryoinic antigen (CEA) has been extensively
targeted in a range of immunotherapy approaches including
antibody targeted T cells (Hombach et al, 1999; Nolan et al, 1999;
Gilham et al, 2002). CEA is expressed to high levels on tumour, yet
is also expressed to far lower levels on normal gastric mucosal
surfaces (Hammarstrom, 1999; Francis et al, 2002). While there has
been no evidence of toxicity in CEA vaccination trials (Berinstein,
2002), clinical trials, which are due to start using antibody targeted
T cells, will assess whether gut toxicity is observed as a part of the
T-cell therapy. In the absence of truly tumour-specific antigens,
any therapy targeting tumour antigens is likely to be associated
with a level of toxicity. The severity of this toxicity remains to be
established and predicting and managing it will be an important
component of any trial protocol. Critically, knowledge of the
normal tissue distribution of the targeted antigen and the relative
level of expression will be important in order to facilitate this
process. In the case of CEA, it is envisaged that the high level of
expression on tumour cells coupled with the low levels of
expression on a restricted distribution of normal cells will mean
that autoimmune toxicities should be minimal.
A final point relates to the use of receptor constructs that encode
multiple signalling domains. Ligation of CD28-z receptor expres-
sing T cells by antigen results in a plethora of signals, which are
intended to improve the survival of the engineered T cell. Given
that normal cells may express TAAs albeit to low levels, there may
be an issue that CD28-z receptor T cells could be continuously
stimulated and therefore produce longer term unwanted side
effects. Once again, the potential toxicity will be balanced by the
theoretical improved cancer killing, which may be generated by
these improved receptor constructs. Until clinical trials have been
carried out against a number of target antigens, it is unclear
whether these potential toxicities pose a real or theoretical risk.
Clinical application
Current clinical trials are testing CD3z and g-based CIRs (Lamers
et al, 2002) with a trial likely to test CD28-z receptors in the near
future. While testing the function of engineered T cells in vivo,
these trials are also aiming to investigate whether the general
approach to gene modification and culture of T cells is feasible.
FUTURE DIRECTIONS
Engineered T-cell therapy is in its infancy, although the approach
is now being tested in early-phase clinical trials. These clinical
investigations are based on observations, which have shown that
engineered T cells (either expressing an engineered TCR or
antibody receptor) can respond against their desired antigens in a
manner that suggests that these T cells may be effective against
cancer in situ. While highly encouraging, these studies also
highlight how little is effectively known about engineered T cells.
Issues such as how best to culture and gene-modify T cells are still
being addressed. The inclusion of cytokines in addition to IL-2
during culture of the T cells is likely to affect the design of clinical
protocols in the near future. Trials with TILs suggest that
persistence of T cells is important (Robbins et al, 2004), and thus
combining the chemotherapy regimes used in TIL trials with
engineered T cells may prove to be of major importance. At a
molecular level, a basic understanding of how engineered T cells
function in response to antigen is also lacking. In addition, the
impact of key immune cells that can dampen the immune response
(such as regulatory T cells) is not known. There is also a lack of
understanding of how gene modification can affect how engineered
T cells survive and traffic in the patient’s circulation. With these
issues in mind, it is likely that combining engineered T cell with
preconditioning chemotherapy, IL-2 support and vaccination
protocols may all contribute to the in vivo effectiveness of this
therapy.
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